Welcome to our dedicated page for Barrick Mining Corporation news (Ticker: B), a resource for investors and traders seeking the latest updates and insights on Barrick Mining Corporation stock.
Barnes Group Inc. (NYSE: B) maintains its position as a global leader in precision industrial technologies and aerospace solutions. This news hub provides investors and industry professionals with essential updates on corporate developments, financial performance, and strategic initiatives.
Access timely updates spanning earnings announcements, product innovations, and operational milestones. Our curated collection features official press releases alongside market analysis relevant to Barnes Grp's industrial and aerospace segments.
Key coverage areas include manufacturing advancements in transportation systems, aerospace component developments, and strategic partnerships across global markets. The repository serves as a reliable resource for understanding the company's impact on sectors ranging from healthcare infrastructure to defense technologies.
Bookmark this page for streamlined access to Barnes Grp's latest financial disclosures and operational updates. Regularly refreshed content ensures stakeholders maintain current awareness of this engineering leader's market position and technological contributions.
Lennar (NYSE: LEN) has partnered with Dandelion Energy to implement one of the largest residential geothermal deployments in US history. The collaboration will integrate Dandelion's geothermal systems into over 1,500 new Lennar homes in Colorado over the next two years.
Homeowners are expected to save approximately $30 million over 20 years compared to air-source heat pumps, offering the lowest monthly energy bills. The initiative benefits from Colorado's state tax credit and Xcel Energy's geothermal programs, significantly reducing up-front costs for homebuilders.
The project aligns with Colorado's clean energy transition goals, promising reduced carbon emissions and lower energy costs. According to the Department of Energy, widespread adoption of geothermal heat pumps could eliminate the need for 24,500 miles of new grid transmission lines.
BioArctic AB (BIOA) announced that the European Commission (EC) has referred the marketing authorization approval decision for lecanemab, their Alzheimer's treatment, to the Appeal Committee. This follows the positive opinion received from the Committee for Medicinal Products for Human Use (CHMP) in February 2025.
If approved, the authorization would extend to all 27 EU member states, plus Iceland, Liechtenstein, and Norway. The drug, marketed as Leqembi, is already approved in several major markets including the US, Japan, China, and Great Britain.
Leqembi was developed through a collaboration between BioArctic and Eisai, based on Professor Lars Lannfelt's discovery of the Arctic mutation in Alzheimer's disease. While Eisai manages clinical development and global commercialization, BioArctic retains rights to commercialize Leqembi in the Nordic region jointly with Eisai.
Integrum AB (Nasdaq First North: INTEG B) has announced a new compensation package for Board Director and Acting CEO Scott Flora, focusing on performance-based incentives during the company's strategic transition. The package includes 200,000 Stock Appreciation Rights (SARs) with a maximum compensation of SEK 60 per SAR and a base price of SEK 29.30.
The SARs will vest at a rate of 20% every three months starting June 1, 2025, and can be exercised between September 1-October 31, 2026. Unvested SARs will lapse without payment. The company maintains flexibility to pay in either stock or cash. As part of this restructuring, Flora's fixed compensation will be reduced. This adjustment aligns with the company's executive compensation guidelines approved at the latest shareholders' meeting.
Hexagon has released its Annual Report and Sustainability Report 2024, now available on hexagon.com. The company plans to distribute the reports digitally, though printed copies can be requested via email or phone. The Annual General Meeting is scheduled for May 5, 2025, at 17:00 CET in Stockholm, with attendance notification required by April 28, 2025.
As a global leader in precision technologies, Hexagon (Nasdaq Stockholm: HEXA B) operates in 50 countries with approximately 24,800 employees and generates net sales of about 5.4bn EUR. The company specializes in digital twins, robotics, and AI solutions for industry transformation.
BioArctic AB (NASDAQ Stockholm: BIOA B) announced that its partner Eisai has released sales projections for Leqembi®. According to Eisai's simulation, Leqembi sales are expected to reach JPY 250 to 280 billion for their financial year 2027, ending March 2028.
Integrum AB (INTEG B) has announced compelling results from a two-year follow-up study conducted by Walter Reed National Military Medical Center on their OPRA™ Implant System for transfemoral amputees. The Level II Evidence study, focusing on the latest version introduced in 2017, demonstrates significant advantages over traditional socket prostheses.
The study revealed several key achievements:
- 100% implant survival rate
- Reduced infection and complication rates compared to previous data
- Increased prosthetic use
- Improved mobility and quality of life for patients
The research, published in Clinical Orthopaedics and Related Research (CORR), was conducted by a team led by Dr. Benjamin K. Potter and Dr. Jonathan Forsberg. The findings are expected to drive further adoption among US health providers and potentially increase insurance provider reimbursement coverage.
BioArctic AB (Nasdaq Stockholm: BIOA B) has received Orphan Drug Designation from the US FDA for exidavnemab, targeting the treatment of Multiple System Atrophy (MSA). MSA is a rare, fatal disease affecting the central and autonomic nervous systems, characterized by alpha-synuclein aggregation that damages brain nerve cells.
Exidavnemab is being developed as a disease-modifying treatment for synucleinopathies including MSA and Parkinson's disease. As a monoclonal antibody, it selectively targets soluble alpha-synuclein aggregates to potentially reduce their spreading and negative effects.
The FDA's Orphan Drug Designation provides several benefits, including:
- Tax credits for qualified clinical trials
- Prescription drug user-fee exemptions
- Potential seven-year marketing exclusivity upon FDA approval
Hexagon AB has appointed Gordon Dale as President of its Autonomous Solutions (AS) division, reporting to interim President and CEO Norbert Hanke. Dale, a 16-year veteran of Hexagon who joined through the NovAtel acquisition, previously served as Chief Synergy Officer where he successfully integrated the Autonomy & Positioning and Mining businesses into the AS division.
Dale brings significant credentials including an MBA and a Bachelor's in Electrical and Computer Engineering. The appointment follows the completion of AS division's integration, aimed at strengthening Hexagon's growth and margin performance. Hexagon, listed on Nasdaq Stockholm as HEXA B, is a global leader in precision technologies with approximately 24,800 employees across 50 countries and net sales of about 5.4bn EUR.
BioArctic AB (Nasdaq Stockholm: BIOA B) founders Lars Lannfelt and Pär Gellerfors, along with CEO Gunilla Osswald, have been awarded Uppsala University's Innovation and Entrepreneurship Prize 2025 for their groundbreaking work in Alzheimer's disease treatment.
The recognition stems from Lannfelt's 1990s breakthrough in understanding Alzheimer's disease and developing an antibody-based treatment. The company, founded in 2003, partnered with Japanese pharmaceutical company Eisai to develop lecanemab, which is now approved in eleven countries including the USA, Japan, and China, with pending approvals in 17 additional countries and regions, including Europe.
The founders' vision includes building BioArctic into a fully-fledged pharmaceutical company in Sweden, focusing on both research and product commercialization. Gunilla Osswald, CEO since 2014, has been instrumental in realizing this vision of helping patients worldwide.
Hexagon AB (HEXA B) has announced plans to separate its Asset Lifecycle Intelligence (ALI) division and related businesses through a Lex Asea distribution to shareholders, with an expected listing on a U.S. national securities exchange in early 2026. The new company ('NewCo') will include the expanded perimeter of Safety, Infrastructure & Geospatial (SIG) division, ETQ business, and Bricsys business.
NewCo will operate as a standalone software and SaaS company, led by Mattias Stenberg. As of December 31, 2024, NewCo had approximately 7,200 employees and revenues of EUR 1,448 million with an adjusted operating margin of 31%. The remaining Hexagon business will retain approximately 17,600 employees with revenues of EUR 3,953 million and an adjusted operating margin of 29%.
The separation process is subject to stakeholder approval, regulatory consents, and other conditions, with completion targeted for first half of 2026. A temporary Swedish Depository Receipt programme will be established via Nasdaq Stockholm to facilitate the transition.
FAQ
What is the current stock price of Barrick Mining Corporation (B)?
What is the market cap of Barrick Mining Corporation (B)?
